In 2012, Heppner's lab reported in Nature Medicine that blocking IL-12 and IL-23 significantly reduced Alzheimer's-related brain changes in mice. "But we couldn't unravel the underlying mechanism ...

Ebdarokimab is the company's first Class 1 new drug approved for autoimmune diseases and the second non-oncology new drug to receive marketing approval, following ebronucimab (PCSK9). This approval ...